Global pharma giant Novo Nordisk has reported positive topline results from its Phase 3a PIONEER TEENS trial, marking a major step forward in the treatment of type 2 diabetes in children and adolescents aged 10–17.
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c—a key marker of blood sugar control—compared with placebo. The company also said the treatment showed a well-tolerated safety profile consistent with earlier semaglutide studies.
Oral semaglutide is already marketed as Rybelsus in the EU and US, and Novo Nordisk said it will be available in the US as an oral version of Ozempic soon, pending regulatory approval.
“Over the past two decades, the prevalence of type 2 diabetes among children and adolescents has increased substantially, yet treatment options for this population remain limited, underscoring a significant unmet need.
"Oral semaglutide has already demonstrated clinically meaningful glycaemic efficacy and a well-established safety profile in adults with type 2 diabetes, alongside proven cardiovascular benefits unique to this molecule,” said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development, at Novo Nordisk.
“These results from the PIONEER TEENS trial confirm that oral semaglutide is an effective treatment option for children and adolescents with type 2 diabetes who require glycaemic control beyond that provided by the current standard of care.”
The findings land against a backdrop of rising childhood metabolic disease. Type 2 diabetes in young people is described as a severe, progressive condition linked to increased risk of early mortality in adulthood. Globally, 14.6 million adolescents were living with the disease in 2021, a figure projected to surge to 20.9 million by 2030.
Current treatment guidelines rely mainly on metformin and insulin. But metformin fails to maintain glycaemic control in roughly half of adolescents, while insulin use can lead to hypoglycaemia and weight gain—highlighting a significant gap in care.
Experts say the study is notable as the first clinical trial of an oral GLP-1 receptor agonist in this age group, potentially opening the door to a new treatment class for younger patients.
“Pending regulatory approvals, oral semaglutide has the potential to be the first and only oral GLP-1 RA to demonstrate superior glycemic efficacy versus placebo in children and adolescents with type 2 diabetes, while maintaining the well-established safety profile seen across the semaglutide portfolio,” the company noted.
The 52-week PIONEER TEENS trial enrolled 132 participants aged 10–17 with type 2 diabetes. Patients received once-daily oral semaglutide at doses of 3 mg, 7 mg, or 14 mg, or placebo, alongside background therapy with metformin, basal insulin, or both. The primary endpoint measured change in HbA1c at 26 weeks.
